methyl 4-[4-(2-adamantylcarbamoyl)-5-methylsulfanylpyrazol-1-yl]benzoate | 1048669-03-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 4-[4-(2-adamantylcarbamoyl)-5-methylsulfanylpyrazol-1-yl]benzoate
• CAS: 1048669-03-9
• 化学式: C₂₃H₂₇N₃O₃S
• 分子量: 425.552
• InChiKey: KSJDWYZNWUQCJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  98.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 4-[4-(2-adamantylcarbamoyl)-5-methylsulfanylpyrazol-1-yl]benzoate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 18.0h， 以75%的产率得到4-[4-(2-adamantylcarbamoyl)-5-methylsulfanyI-pyrazol-1-yl]benzoic acid
  参考文献：
  名称：

  Novel Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor with Reduced Acyl Glucuronide Liability: The Discovery of 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic Acid (AZD8329)

  摘要：

  Inhibition of 11 beta-HSD1 is viewed as a potential target for the treatment of obesity and other elements of the metabolic syndrome. We report here the optimization of a carboxylic acid class of inhibitors from AZD4017 (1) to the development candidate AZD8329 (27). A structural change from pyridine to pyrazole together with structural optimization led to an improved technical profile in terms of both solubility and pharmacokinetics. The extent of acyl glucuronidation was reduced through structural optimization of both the carboxylic acid and amide substituents, coupled with a reduction in lipophilicity leading to an overall increase in metabolic stability.

  DOI：

  10.1021/jm301252n
• 作为产物：
  描述：

  tert-butyl 5-amino-1-(4-methoxycarbonylphenyl)pyrazole-4-carboxylate 在 亚硝酸特丁酯 、 sodium hexamethyldisilazane 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 copper dichloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 26.75h， 生成 methyl 4-[4-(2-adamantylcarbamoyl)-5-methylsulfanylpyrazol-1-yl]benzoate
  参考文献：
  名称：

  Novel Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor with Reduced Acyl Glucuronide Liability: The Discovery of 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic Acid (AZD8329)

  摘要：

  Inhibition of 11 beta-HSD1 is viewed as a potential target for the treatment of obesity and other elements of the metabolic syndrome. We report here the optimization of a carboxylic acid class of inhibitors from AZD4017 (1) to the development candidate AZD8329 (27). A structural change from pyridine to pyrazole together with structural optimization led to an improved technical profile in terms of both solubility and pharmacokinetics. The extent of acyl glucuronidation was reduced through structural optimization of both the carboxylic acid and amide substituents, coupled with a reduction in lipophilicity leading to an overall increase in metabolic stability.

  DOI：

  10.1021/jm301252n

文献信息

• PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS
  申请人：Packer Martin John

  公开号：US20090221663A1

  公开（公告）日：2009-09-03

  A compound of Formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  公式（I）的化合物及其药学上可接受的盐，其中可变基团在其内部定义；还描述了它们在抑制11βHSD1方面的用途，制造它们的过程以及包含它们的制药组合物。
• Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors
  申请人：Packer Martin John

  公开号：US20110224273A1

  公开（公告）日：2011-09-15

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  化合物I的式子及其药用可接受的盐，其中变量基团在定义范围内；还描述了它们在抑制11βHSD1方面的使用，制造它们的过程以及包含它们的制药组合物。
• Pyrazole derivatives as 11-beta-HSD1 inhibitors
  申请人：AstraZeneca AB (Publ)

  公开号：EP2292228A1

  公开（公告）日：2011-03-09

  A compound of formula (I): and pharmaceutically -acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  式 (I) 的化合物： 及其药学上可接受的盐，其中的可变基团在其中定义；还描述了它们在抑制 11βHSD1 中的用途、制造工艺以及包含它们的药物组合物。
• US7816391B2
  申请人：——

  公开号：US7816391B2

  公开（公告）日：2010-10-19
• US8344016B2
  申请人：——

  公开号：US8344016B2

  公开（公告）日：2013-01-01